



REPORTED SALES vs. PRIOR PERIOD (\$MM)

	FIRST QUARTER				
	2016	2015	% Change		
			Reported	Operational <sup>(1)</sup>	Currency
<b>CONSUMER SEGMENT <sup>(2)</sup></b>					
<b>BABY CARE</b>					
US	\$ 95	111	-14.4%	-14.4%	-
Intl	356	400	-11.0%	0.1%	-11.1%
WW	451	511	-11.7%	-3.0%	-8.7%
<b>ORAL CARE</b>					
US	170	158	7.6%	7.6%	-
Intl	215	245	-12.2%	-2.9%	-9.3%
WW	385	403	-4.5%	1.1%	-5.6%
<b>OTC</b>					
US	461	405	13.8%	13.8%	-
Intl	558	588	-5.1%	2.8%	-7.9%
WW	1,019	993	2.6%	7.3%	-4.7%
<b>SKIN CARE</b>					
US	488	492	-0.8%	-0.8%	-
Intl	374	411	-9.0%	-0.7%	-8.3%
WW	862	903	-4.5%	-0.7%	-3.8%
<b>WOMEN'S HEALTH</b>					
US	6	6	0.0%	0.0%	-
Intl	245	281	-12.8%	-0.9%	-11.9%
WW	251	287	-12.5%	-0.9%	-11.6%
<b>WOUND CARE / OTHER</b>					
US	138	187	-26.2%	-26.2%	-
Intl	89	106	-16.0%	-8.4%	-7.6%
WW	227	293	-22.5%	-19.7%	-2.8%
<b>TOTAL CONSUMER</b>					
US	1,358	1,359	-0.1%	-0.1%	-
Intl	1,837	2,031	-9.6%	-0.3%	-9.3%
WW	\$ 3,195	3,390	-5.8%	-0.2%	-5.6%

See footnotes at end of schedule

**REPORTED SALES vs. PRIOR PERIOD (\$MM)**

	FIRST QUARTER				
	<u>2016</u>	<u>2015</u>	<u>% Change</u>		
			<u>Reported</u>	<u>Operational</u> <sup>(1)</sup>	<u>Currency</u>
<b>PHARMACEUTICAL SEGMENT <sup>(2)</sup></b>					
<b>IMMUNOLOGY</b>					
US	\$ 2,171	1,755	23.7%	23.7%	-
Intl	739	708	4.4%	12.8%	-8.4%
WW	<u>2,910</u>	<u>2,463</u>	18.1%	20.5%	-2.4%
<b>REMICADE</b>					
US	1,211	1,055	14.8%	14.8%	-
US Exports <sup>(3)</sup>	233	181	28.7%	28.7%	-
Intl	335	364	-8.0%	1.8%	-9.8%
WW	<u>1,779</u>	<u>1,600</u>	11.2%	13.4%	-2.2%
<b>SIMPONI / SIMPONI ARIA</b>					
US	216	155	39.4%	39.4%	-
Intl	174	145	20.0%	27.6%	-7.6%
WW	<u>390</u>	<u>300</u>	30.0%	33.7%	-3.7%
<b>STELARA</b>					
US	511	364	40.4%	40.4%	-
Intl	224	185	21.1%	27.3%	-6.2%
WW	<u>735</u>	<u>549</u>	33.9%	36.0%	-2.1%
<b>OTHER IMMUNOLOGY</b>					
US	-	-	-	-	-
Intl	6	14	-57.1%	-48.4%	-8.7%
WW	<u>6</u>	<u>14</u>	-57.1%	-48.4%	-8.7%
<b>INFECTIOUS DISEASES</b>					
US	358	412	-13.1%	-13.1%	-
Intl	418	563	-25.8%	-22.1%	-3.7%
WW	<u>776</u>	<u>975</u>	-20.4%	-18.2%	-2.2%
<b>EDURANT</b>					
US	11	9	22.2%	22.2%	-
Intl	108	82	31.7%	35.3%	-3.6%
WW	<u>119</u>	<u>91</u>	30.8%	34.1%	-3.3%
<b>OLYSIO / SOVRIAD</b>					
US	16	98	-83.7%	-83.7%	-
Intl	16	136	-88.2%	-87.1%	-1.1%
WW	<u>32</u>	<u>234</u>	-86.3%	-85.7%	-0.6%
<b>PREZISTA / PREZCOBIX / REZOLSTA</b>					
US	277	234	18.4%	18.4%	-
Intl	175	193	-9.3%	-4.6%	-4.7%
WW	<u>452</u>	<u>427</u>	5.9%	8.0%	-2.1%
<b>OTHER INFECTIOUS DISEASES</b>					
US	54	71	-23.9%	-23.9%	-
Intl	119	152	-21.7%	-16.7%	-5.0%
WW	<u>173</u>	<u>223</u>	-22.4%	-19.0%	-3.4%

**REPORTED SALES vs. PRIOR PERIOD (\$MM)**

	<b>FIRST QUARTER</b>				
	<u>2016</u>	<u>2015</u>	<u>% Change</u>		
			<u>Reported</u>	<u>Operational <sup>(1)</sup></u>	<u>Currency</u>
<b><u>NEUROSCIENCE</u></b>					
US	680	750	-9.3%	-9.3%	-
Intl	869	868	0.1%	5.4%	-5.3%
WW	<u>1,549</u>	<u>1,618</u>	-4.3%	-1.4%	-2.9%
<b><u>CONCERTA / METHYLPHENIDATE</u></b>					
US	134	126	6.3%	6.3%	-
Intl	97	98	-1.0%	6.4%	-7.4%
WW	<u>231</u>	<u>224</u>	3.1%	6.3%	-3.2%
<b><u>INVEGA / PALIPERIDONE</u></b>					
US	24	94	-74.5%	-74.5%	-
Intl	62	61	1.6%	5.3%	-3.7%
WW	<u>86</u>	<u>155</u>	-44.5%	-43.0%	-1.5%
<b><u>INVEGA SUSTENNA / XEPLION / INVEGA TRINZA</u></b>					
US	305	228	33.8%	33.8%	-
Intl	208	183	13.7%	19.3%	-5.6%
WW	<u>513</u>	<u>411</u>	24.8%	27.3%	-2.5%
<b><u>RISPERDAL CONSTA</u></b>					
US	95	104	-8.7%	-8.7%	-
Intl	136	150	-9.3%	-4.9%	-4.4%
WW	<u>231</u>	<u>254</u>	-9.1%	-6.5%	-2.6%
<b><u>OTHER NEUROSCIENCE</u></b>					
US	122	198	-38.4%	-38.4%	-
Intl	366	376	-2.7%	2.6%	-5.3%
WW	<u>488</u>	<u>574</u>	-15.0%	-11.5%	-3.5%
<b><u>ONCOLOGY</u></b>					
US	549	334	64.4%	64.4%	-
Intl	805	774	4.0%	9.8%	-5.8%
WW	<u>1,354</u>	<u>1,108</u>	22.2%	26.3%	-4.1%
<b><u>IMBRUVICA</u></b>					
US	132	66	100.0%	100.0%	-
Intl	129	50	*	*	**
WW	<u>261</u>	<u>116</u>	*	*	**
<b><u>VELCADE</u></b>					
US	-	-	-	-	-
Intl	304	339	-10.3%	-5.4%	-4.9%
WW	<u>304</u>	<u>339</u>	-10.3%	-5.4%	-4.9%
<b><u>ZYTIGA</u></b>					
US	272	253	7.5%	7.5%	-
Intl	286	303	-5.6%	-0.1%	-5.5%
WW	<u>558</u>	<u>556</u>	0.4%	3.4%	-3.0%
<b><u>OTHER ONCOLOGY</u></b>					
US	145	15	*	*	-
Intl	86	82	4.9%	11.2%	-6.3%
WW	<u>231</u>	<u>97</u>	*	*	**

**REPORTED SALES vs. PRIOR PERIOD (\$MM)**

	<b>FIRST QUARTER</b>				
	<u>2016</u>	<u>2015</u>	<u>% Change</u>		
			<u>Reported</u>	<u>Operational <sup>(1)</sup></u>	<u>Currency</u>
<b><u>CARDIOVASCULAR / METABOLISM / OTHER</u></b>					
US	1,179	1,120	5.3%	5.3%	-
Intl	410	442	-7.2%	-0.4%	-6.8%
WW	<u>1,589</u>	<u>1,562</u>	1.7%	3.6%	-1.9%
<b><u>XARELTO</u></b>					
US	567	441	28.6%	28.6%	-
Intl	-	-	-	-	-
WW	<u>567</u>	<u>441</u>	28.6%	28.6%	-
<b><u>INVOKANA / INVOKAMET</u></b>					
US	297	266	11.7%	11.7%	-
Intl	28	12	*	*	**
WW	<u>325</u>	<u>278</u>	16.9%	17.8%	-0.9%
<b><u>PROCRIT / EPREX</u></b>					
US	183	163	12.3%	12.3%	-
Intl	91	106	-14.2%	-8.7%	-5.5%
WW	<u>274</u>	<u>269</u>	1.9%	4.1%	-2.2%
<b><u>OTHER</u></b>					
US	132	250	-47.2%	-47.2%	-
Intl	291	324	-10.2%	-3.5%	-6.7%
WW	<u>423</u>	<u>574</u>	-26.3%	-22.5%	-3.8%
<b><u>TOTAL PHARMACEUTICAL</u></b>					
US	4,937	4,371	12.9%	12.9%	-
Intl	3,241	3,355	-3.4%	2.6%	-6.0%
WW	<u>\$ 8,178</u>	<u>7,726</u>	5.9%	8.5%	-2.6%

See footnotes at end of schedule

**REPORTED SALES vs. PRIOR PERIOD (\$MM)**

	<b>FIRST QUARTER</b>				
	<u>2016</u>	<u>2015</u>	<u>% Change</u>		
			<u>Reported</u>	<u>Operational <sup>(1)</sup></u>	<u>Currency</u>
<b><u>MEDICAL DEVICES <sup>(2) (4)</sup></u></b>					
<b><u>CARDIOVASCULAR</u></b>					
US	\$ 231	228	1.3%	1.3%	-
Intl	212	301	-29.6%	-26.3%	-3.3%
WW	<u>443</u>	<u>529</u>	-16.3%	-14.4%	-1.9%
<b><u>DIABETES CARE</u></b>					
US	180	212	-15.1%	-15.1%	-
Intl	249	272	-8.5%	-2.8%	-5.7%
WW	<u>429</u>	<u>484</u>	-11.4%	-8.2%	-3.2%
<b><u>DIAGNOSTICS</u></b>					
US	-	-	-	-	-
Intl	28	30	**	**	**
WW	<u>28</u>	<u>30</u>	**	**	**
<b><u>ORTHOPAEDICS</u></b>					
US	1,392	1,309	6.3%	6.3%	-
Intl	949	1,019	-6.9%	-1.4%	-5.5%
WW	<u>2,341</u>	<u>2,328</u>	0.6%	3.0%	-2.4%
<b><u>HIPS</u></b>					
US	203	190	6.8%	6.8%	-
Intl	139	143	-2.8%	3.4%	-6.2%
WW	<u>342</u>	<u>333</u>	2.7%	5.4%	-2.7%
<b><u>KNEES</u></b>					
US	244	226	8.0%	8.0%	-
Intl	145	150	-3.3%	2.1%	-5.4%
WW	<u>389</u>	<u>376</u>	3.5%	5.7%	-2.2%
<b><u>TRAUMA</u></b>					
US	381	364	4.7%	4.7%	-
Intl	261	292	-10.6%	-4.9%	-5.7%
WW	<u>642</u>	<u>656</u>	-2.1%	0.4%	-2.5%
<b><u>SPINE &amp; OTHER</u></b>					
US	564	529	6.6%	6.6%	-
Intl	404	434	-6.9%	-1.8%	-5.1%
WW	<u>968</u>	<u>963</u>	0.5%	2.8%	-2.3%

**REPORTED SALES vs. PRIOR PERIOD (\$MM)**

	<b>FIRST QUARTER</b>				
	<u>2016</u>	<u>2015</u>	<u>% Change</u>		
			<u>Reported</u>	<u>Operational <sup>(1)</sup></u>	<u>Currency</u>
<b><u>SURGERY</u></b>					
US	981	960	2.2%	2.2%	-
Intl	1,247	1,296	-3.8%	2.3%	-6.1%
WW	<u>2,228</u>	<u>2,256</u>	-1.2%	2.3%	-3.5%
<b><u>ADVANCED</u></b>					
US	352	329	7.0%	7.0%	-
Intl	464	441	5.2%	11.7%	-6.5%
WW	<u>816</u>	<u>770</u>	6.0%	9.7%	-3.7%
<b><u>GENERAL</u></b>					
US	419	422	-0.7%	-0.7%	-
Intl	651	711	-8.4%	-2.8%	-5.6%
WW	<u>1,070</u>	<u>1,133</u>	-5.6%	-2.1%	-3.5%
<b><u>SPECIALTY</u></b>					
US	210	209	0.5%	0.5%	-
Intl	132	144	-8.3%	-1.0%	-7.3%
WW	<u>342</u>	<u>353</u>	-3.1%	-0.1%	-3.0%
<b><u>VISION CARE</u></b>					
US	242	253	-4.3%	-4.3%	-
Intl	398	378	5.3%	9.8%	-4.5%
WW	<u>640</u>	<u>631</u>	1.4%	4.1%	-2.7%
<b><u>TOTAL MEDICAL DEVICES</u></b>					
US	3,026	2,962	2.2%	2.2%	-
Intl	3,083	3,296	-6.5%	-1.0%	-5.5%
WW	<u>\$ 6,109</u>	<u>6,258</u>	-2.4%	0.5%	-2.9%

\* Percentage greater than 100%

\*\* Not meaningful

(1) Operational growth excludes the effect of translational currency

(2) Unaudited

(3) Reported as U.S. sales

(4) Prior year amounts have been reclassified to conform to current year product disclosure